WASHINGTON, D.C. – In response to the Biden administration’s announcement today of its plan to expand COVID-19 testing in our nation’s K-8 schools, AdvaMed — the world’s largest trade association representing medical technology companies — released the following statements from AdvaMed President and CEO Scott Whitaker and Susan Van Meter, executive director of AdvaMedDx, the division within AdvaMed that represents diagnostic testing companies:
You are here
WASHINGTON, D.C. – AdvaMedDx, the division within AdvaMed representing manufacturers of in vitro diagnostic tests, foundational to the delivery of quality health care, announced that Norman Schwartz, President & CEO of Bio-Rad Laboratories, Inc. and founding Board member of AdvaMedDx, has been named chair of the AdvaMedDx Board of Directors for a two-year term.
WASHINGTON, D.C. –New data from AdvaMed’s COVID-19 Diagnostic Supply Registry reveals that total U.S. shipments of COVID-19 molecular diagnostic tests have reached 200 million. A breakdown of the data shows that innovative diagnostics companies are shipping, on average, over 1.4 million molecular tests each day.